This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Charité – Universitätsmedizin Berlin, Rhythm Pharmaceuticals, Inc.. Active years: 2021.
Company Filing History:
1 out of 283 
1 out of 12 
Years Active: 2021
Title: Peter Kuhnen: Innovating Treatments for Melanocortin-4 Receptor Pathway Disorders
Introduction
Peter Kuhnen is an accomplished inventor based in Berlin, Germany, known for his significant contributions to medical science, particularly in the field of treating disorders associated with the melanocortin-4 receptor (MC4R) pathway. With a singular patent to his name, Kuhnen is dedicated to finding solutions for conditions such as Prader Willi Syndrome (PWS), obesity, and hyperphagia.
Latest Patents
Kuhnen’s patent, titled "Method of treating melanocortin-4 receptor pathway-associated disorders," focuses on using a melanocortin-4 receptor agonist to treat various disorders. The invention details methods for treating subjects with deficiencies in the pro-opiomelanocortin (POMC)-MC4R pathway, specifically targeting individuals who are POMC-null or PCSK-null. This innovative approach holds promise for improving the quality of life for affected individuals.
Career Highlights
Throughout his career, Peter Kuhnen has worked with notable organizations, including Rhythm Pharmaceuticals, Inc. and Charité - Universitätsmedizin Berlin. His work at these institutions has positioned him at the forefront of research and innovation in the treatment of metabolic disorders, showcasing his commitment to medical advancement.
Collaborations
Kuhnen has collaborated with esteemed professionals such as Leonardus H.T. Van Der Ploeg and Bart Henderson, further enhancing the breadth and impact of his research. These collaborations underscore the importance of teamwork in advancing scientific knowledge and developing effective therapies.
Conclusion
Peter Kuhnen's contributions to the field of pharmacology through his innovative patent illuminate the potential for new treatments for melanocortin-4 receptor pathway-associated disorders. His dedication to medical research and collaboration with other experts reflects a promising future for innovative therapies aimed at improving patient outcomes.